Back to NAI500

Company Profile

Founded in 2011 with three locations including Guangzhou and Taizhou, P.R China. The founder of the company and the management team members had served transnational companies including Pfizer, GSK and AstraZeneca with successful new drug products development experience. There are 190 employees including 7 Ph.D.s with their education from US, Canada and Europe. OPL is using 6 CMOs for commercial and for NDA batch manufacture. 10 CROs from US, Canada, Indian and P.R. China are conducting clinical trials for OPL. OPL is a specialty pharmaceutical company whose main business is to apply proprietary technologies to develop NDA products which are safer, more efficacious and better patient compliance to meet the unmet clinical needs. OPL strives to become a world leader in development of modified release technologies and in application of these technologies for new drug product development.

Corporate Speaker

Dr. Xiaoguang (Gilbert) Wen

Founder, Chairman & CEO

Dr. Gilbert Wen is the founder of Overseas Pharmaceuticals Ltd, a specialty pharmaceutical company focusing on developing modified release platform technologies and applying these proprietary technologies to develop NDA products in collaboration with transnational pharmaceutical companies. Among many honors and recognitions, Dr. Wen is a distinguished expert of the Thousand Talent Program (entrepreneurial category) in China and a committee member of Pharmaceutics in Chinese Pharmaceutical Association. In addition, Dr. Wen is a recipient of Distinguished Alumni of Medical School of Beijing University. He holds 17 international and national granted patents and authored a chapter in the book “Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice.”

Dr. Wen has previously worked as a formulation scientist in the Product Line Extension division at GSK and in the R&D headquarter for Consumer Health Care Division at Pfizer (Wyeth). After returning to China, he became the head of the State Key Laboratory of Ministry of Science and Technology for Advanced and Novel Controlled Release Technologies and also served as an executive director at Wuxi Apptech.

Company Website